Quantcast
Last updated on April 18, 2014 at 1:21 EDT

Latest Salmeterol Stories

2014-04-07 12:23:29

LISBON, Portugal, April 7, 2014 /PRNewswire/ -- Hovione announced today that the United States Patent and Trademark Office (USPTO) has granted a patent for a capsule-based, low-cost dry powder inhaler (DPI) to Hovione. This happened less than three years after the patent was filed and after just one Office Action - unusual speed for an inhaler application. Hovione have designed this inhaler to have just two operating components, thereby achieving...

2014-01-20 12:24:00

LONDON, Jan. 20, 2014 /PRNewswire/ -- Reportbuyer.com just published a new market research report: Asthma Therapeutics Market to 2019 - Breakthrough Biologics to Enhance Treatment of Severe Asthma and Drive Market Growth Asthma Therapeutics Market to 2019 - Breakthrough Biologics to Enhance Treatment of Severe Asthma and Drive Market Growth Summary GBI Research, a leading business intelligence provider, has released its latest research report, "Asthma Therapeutics Market to 2019 -...

2013-11-11 08:28:31

Resources Available to Help Take Control WILMINGTON, Del., Nov. 11, 2013 /PRNewswire/ -- For many Americans, breathing is a challenge. Over 12 million have chronic obstructive pulmonary disease (COPD)( )and live with symptoms, including constant coughing, wheezing, and shortness of breath. But with an additional 12 million Americans remaining undiagnosed, recognizing COPD signs and symptoms and seeking help is an important health priority. To view the multimedia assets associated with this...

2013-10-30 12:25:42

RESEARCH TRIANGLE PARK, N.C. and SOUTH SAN FRANCISCO, Calif., Oct. 30, 2013 /PRNewswire/ -- GlaxoSmithKline plc (LSE/NYSE: GSK) and Theravance, Inc. (NASDAQ: THRX) today announced that BREO ELLIPTA, a once-daily prescription medicine for chronic obstructive pulmonary disease (COPD), is now available to pharmacies throughout the U.S. BREO ELLIPTA is a combination of the inhaled corticosteroid (ICS), fluticasone furoate "FF", and the long-acting beta(2)-agonist (LABA),...

2013-10-10 16:24:10

ALBANY, New York, October 10, 2013 /PRNewswire/ -- New Report Added in ResearchMoz Reports Database Asthma Therapeutics Market to 2019 - Breakthrough Biologics to Enhance Treatment of Severe Asthma and Drive Market Growth ResearchMoz announces that it has published a new study Asthma Therapeutics Market to 2019 - Breakthrough Biologics to Enhance Treatment of Severe Asthma and Drive Market Growth...

2013-05-13 16:27:10

WILMINGTON, Del., May 13, 2013 /PRNewswire/ -- Approximately 25 million Americans suffer from asthma, which accounts for more than 3300 deaths each year. AstraZeneca (NYSE: AZN) is urging Americans to embrace National Asthma & Allergy Awareness Month this May by taking proactive steps to gain control of their asthma and learn more about how it may be impacting their lives. To view the multimedia assets associated with this release, please click:...

2013-05-10 16:24:28

LONDON and SOUTH SAN FRANCISCO, Calif., May 10, 2013 /PRNewswire/ -- GlaxoSmithKline plc (LSE/NYSE: GSK) and Theravance, Inc. (NASDAQ: THRX) today announced that the US Food and Drug Administration (FDA) has approved BREO(TM) ELLIPTA(TM) as an inhaled long-term, once-daily maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema. It is also indicated to reduce exacerbations of COPD in patients...

2013-04-02 12:31:20

Patent Portfolio Further Strengthened by Notice of Allowance for LIPO-202 SAN DIEGO, April 2, 2013 /PRNewswire/ -- Lithera, Inc., a clinical stage pharmaceutical company focused on lifestyle and medical indications in aesthetic medicine and ophthalmology, today announced significant advances in the patent estate covering LIPO-202 (Salmeterol Xinafoate for Injection), the company's lead product candidate under development for localized, non-ablative reduction of subcutaneous fat....

2012-12-11 21:27:26

Advantages in relation to acute exacerbations, hospitalizations, symptoms and quality of life In order to widen the narrowed airways in patients with chronic obstructive pulmonary disease (COPD), tiotropium bromide (tiotropium in brief) is one of the drugs available that can be prescribed for inhalation. The German Institute for Quality and Efficiency in Health Care (IQWiG) has examined whether tiotropium offers a perceptible advantage to patients compared to a dummy medication (placebo)...

2012-03-19 10:24:55

EAST HANOVER, N.J., March 19, 2012 /PRNewswire/ -- Novartis Pharmaceuticals Corporation today announced that once-daily Arcapta(TM) Neohaler(TM) (indacaterol inhalation powder) 75 mcg is now available in the US and in pharmacies nationwide. Arcapta Neohaler is indicated for the long-term maintenance bronchodilator treatment of airflow obstruction in adult patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema. Arcapta Neohaler is not...